Résumé
Percutaneous coronary intervention (PCI) was introduced in the late 1970s and the first Bare metal stent (BMS) was implanted by Pr Jacques Puel in 1986. Drug eluting stent (DES) were developed to address the restenosis encountered with BMS. This new device permits an important reduction of restenosis, however very late stent thromboses were observed with the first generation of DES. The new generation of DES was developed with improvement of stent and polymer technology with a better clinical profile in comparison with first generation of DES. The new generation of DES permits in elective PCI a reduction of duration of dual antiplatelet therapy to 3-6 months. In the same time, complete bioresorbable stents are now available but cannot being to be proposed in all clinical situations.